Loss-of-function mutations in cardiac ryanodine receptor channel cause various types of arrhythmias including long QT syndrome
Abstract Aims Gain-of-function mutations in RYR2, encoding the cardiac ryanodine receptor channel (RyR2), cause catecholaminergic polymorphic ventricular tachycardia (CPVT). Whereas, genotype–phenotype correlations of loss-of-function mutations remains unknown, due to a small number of analysed muta...
Saved in:
Published in | Europace (London, England) Vol. 24; no. 3; pp. 497 - 510 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Oxford University Press
02.03.2022
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Abstract
Aims
Gain-of-function mutations in RYR2, encoding the cardiac ryanodine receptor channel (RyR2), cause catecholaminergic polymorphic ventricular tachycardia (CPVT). Whereas, genotype–phenotype correlations of loss-of-function mutations remains unknown, due to a small number of analysed mutations. In this study, we aimed to investigate their genotype–phenotype correlations in patients with loss-of-function RYR2 mutations.
Methods and results
We performed targeted gene sequencing for 710 probands younger than 16-year-old with inherited primary arrhythmia syndromes (IPAS). RYR2 mutations were identified in 63 probands, and 3 probands displayed clinical features different from CPVT. A proband with p.E4146D developed ventricular fibrillation (VF) and QT prolongation whereas that with p.S4168P showed QT prolongation and bradycardia. Another proband with p.S4938F showed short-coupled variant of torsade de pointes (scTdP). To evaluate the functional alterations in these three mutant RyR2s and p.K4594Q previously reported in a long QT syndrome (LQTS), we measured Ca2+ signals in HEK293 cells and HL-1 cardiomyocytes as well as Ca2+-dependent [3H]ryanodine binding. All mutant RyR2s demonstrated a reduced Ca2+ release, an increased endoplasmic reticulum Ca2+, and a reduced [3H]ryanodine binding, indicating loss-of-functions. In HL-1 cells, the exogenous expression of S4168P and K4594Q reduced amplitude of Ca2+ transients without inducing Ca2+ waves, whereas that of E4146D and S4938F evoked frequent localized Ca2+ waves.
Conclusion
Loss-of-function RYR2 mutations may be implicated in various types of arrhythmias including LQTS, VF, and scTdP, depending on alteration of the channel activity. Search of RYR2 mutations in IPAS patients clinically different from CPVT will be a useful strategy to effectively discover loss-of-function RYR2 mutations.
Graphical Abstract |
---|---|
AbstractList | Abstract
Aims
Gain-of-function mutations in RYR2, encoding the cardiac ryanodine receptor channel (RyR2), cause catecholaminergic polymorphic ventricular tachycardia (CPVT). Whereas, genotype–phenotype correlations of loss-of-function mutations remains unknown, due to a small number of analysed mutations. In this study, we aimed to investigate their genotype–phenotype correlations in patients with loss-of-function RYR2 mutations.
Methods and results
We performed targeted gene sequencing for 710 probands younger than 16-year-old with inherited primary arrhythmia syndromes (IPAS). RYR2 mutations were identified in 63 probands, and 3 probands displayed clinical features different from CPVT. A proband with p.E4146D developed ventricular fibrillation (VF) and QT prolongation whereas that with p.S4168P showed QT prolongation and bradycardia. Another proband with p.S4938F showed short-coupled variant of torsade de pointes (scTdP). To evaluate the functional alterations in these three mutant RyR2s and p.K4594Q previously reported in a long QT syndrome (LQTS), we measured Ca2+ signals in HEK293 cells and HL-1 cardiomyocytes as well as Ca2+-dependent [3H]ryanodine binding. All mutant RyR2s demonstrated a reduced Ca2+ release, an increased endoplasmic reticulum Ca2+, and a reduced [3H]ryanodine binding, indicating loss-of-functions. In HL-1 cells, the exogenous expression of S4168P and K4594Q reduced amplitude of Ca2+ transients without inducing Ca2+ waves, whereas that of E4146D and S4938F evoked frequent localized Ca2+ waves.
Conclusion
Loss-of-function RYR2 mutations may be implicated in various types of arrhythmias including LQTS, VF, and scTdP, depending on alteration of the channel activity. Search of RYR2 mutations in IPAS patients clinically different from CPVT will be a useful strategy to effectively discover loss-of-function RYR2 mutations. Abstract Aims Gain-of-function mutations in RYR2, encoding the cardiac ryanodine receptor channel (RyR2), cause catecholaminergic polymorphic ventricular tachycardia (CPVT). Whereas, genotype–phenotype correlations of loss-of-function mutations remains unknown, due to a small number of analysed mutations. In this study, we aimed to investigate their genotype–phenotype correlations in patients with loss-of-function RYR2 mutations. Methods and results We performed targeted gene sequencing for 710 probands younger than 16-year-old with inherited primary arrhythmia syndromes (IPAS). RYR2 mutations were identified in 63 probands, and 3 probands displayed clinical features different from CPVT. A proband with p.E4146D developed ventricular fibrillation (VF) and QT prolongation whereas that with p.S4168P showed QT prolongation and bradycardia. Another proband with p.S4938F showed short-coupled variant of torsade de pointes (scTdP). To evaluate the functional alterations in these three mutant RyR2s and p.K4594Q previously reported in a long QT syndrome (LQTS), we measured Ca2+ signals in HEK293 cells and HL-1 cardiomyocytes as well as Ca2+-dependent [3H]ryanodine binding. All mutant RyR2s demonstrated a reduced Ca2+ release, an increased endoplasmic reticulum Ca2+, and a reduced [3H]ryanodine binding, indicating loss-of-functions. In HL-1 cells, the exogenous expression of S4168P and K4594Q reduced amplitude of Ca2+ transients without inducing Ca2+ waves, whereas that of E4146D and S4938F evoked frequent localized Ca2+ waves. Conclusion Loss-of-function RYR2 mutations may be implicated in various types of arrhythmias including LQTS, VF, and scTdP, depending on alteration of the channel activity. Search of RYR2 mutations in IPAS patients clinically different from CPVT will be a useful strategy to effectively discover loss-of-function RYR2 mutations. Graphical Abstract Gain-of-function mutations in RYR2, encoding the cardiac ryanodine receptor channel (RyR2), cause catecholaminergic polymorphic ventricular tachycardia (CPVT). Whereas, genotype-phenotype correlations of loss-of-function mutations remains unknown, due to a small number of analysed mutations. In this study, we aimed to investigate their genotype-phenotype correlations in patients with loss-of-function RYR2 mutations. We performed targeted gene sequencing for 710 probands younger than 16-year-old with inherited primary arrhythmia syndromes (IPAS). RYR2 mutations were identified in 63 probands, and 3 probands displayed clinical features different from CPVT. A proband with p.E4146D developed ventricular fibrillation (VF) and QT prolongation whereas that with p.S4168P showed QT prolongation and bradycardia. Another proband with p.S4938F showed short-coupled variant of torsade de pointes (scTdP). To evaluate the functional alterations in these three mutant RyR2s and p.K4594Q previously reported in a long QT syndrome (LQTS), we measured Ca2+ signals in HEK293 cells and HL-1 cardiomyocytes as well as Ca2+-dependent [3H]ryanodine binding. All mutant RyR2s demonstrated a reduced Ca2+ release, an increased endoplasmic reticulum Ca2+, and a reduced [3H]ryanodine binding, indicating loss-of-functions. In HL-1 cells, the exogenous expression of S4168P and K4594Q reduced amplitude of Ca2+ transients without inducing Ca2+ waves, whereas that of E4146D and S4938F evoked frequent localized Ca2+ waves. Loss-of-function RYR2 mutations may be implicated in various types of arrhythmias including LQTS, VF, and scTdP, depending on alteration of the channel activity. Search of RYR2 mutations in IPAS patients clinically different from CPVT will be a useful strategy to effectively discover loss-of-function RYR2 mutations. AIMSGain-of-function mutations in RYR2, encoding the cardiac ryanodine receptor channel (RyR2), cause catecholaminergic polymorphic ventricular tachycardia (CPVT). Whereas, genotype-phenotype correlations of loss-of-function mutations remains unknown, due to a small number of analysed mutations. In this study, we aimed to investigate their genotype-phenotype correlations in patients with loss-of-function RYR2 mutations. METHODS AND RESULTSWe performed targeted gene sequencing for 710 probands younger than 16-year-old with inherited primary arrhythmia syndromes (IPAS). RYR2 mutations were identified in 63 probands, and 3 probands displayed clinical features different from CPVT. A proband with p.E4146D developed ventricular fibrillation (VF) and QT prolongation whereas that with p.S4168P showed QT prolongation and bradycardia. Another proband with p.S4938F showed short-coupled variant of torsade de pointes (scTdP). To evaluate the functional alterations in these three mutant RyR2s and p.K4594Q previously reported in a long QT syndrome (LQTS), we measured Ca2+ signals in HEK293 cells and HL-1 cardiomyocytes as well as Ca2+-dependent [3H]ryanodine binding. All mutant RyR2s demonstrated a reduced Ca2+ release, an increased endoplasmic reticulum Ca2+, and a reduced [3H]ryanodine binding, indicating loss-of-functions. In HL-1 cells, the exogenous expression of S4168P and K4594Q reduced amplitude of Ca2+ transients without inducing Ca2+ waves, whereas that of E4146D and S4938F evoked frequent localized Ca2+ waves. CONCLUSIONLoss-of-function RYR2 mutations may be implicated in various types of arrhythmias including LQTS, VF, and scTdP, depending on alteration of the channel activity. Search of RYR2 mutations in IPAS patients clinically different from CPVT will be a useful strategy to effectively discover loss-of-function RYR2 mutations. |
Author | Hoshiai, Minako Aoki, Hisaaki Sakurai, Takashi Horie, Minoru Tetsuo, Naoyuki Wada, Yuko Ohno, Seiko Makiyama, Takeru Kato, Koichi Hirose, Sayako Yoshinaga, Masao Murayama, Takashi Wuriyanghai, Yimin Kurebayashi, Nagomi Kimura, Takeshi Fukuyama, Megumi Kise, Hiroaki |
Author_xml | – sequence: 1 givenname: Sayako surname: Hirose fullname: Hirose, Sayako organization: Department of Bioscience and Genetics, National Cerebral and Cardiovascular Center, 6-1 Kishibe-Shinmachi, Suita, Osaka 564-8565, Japan – sequence: 2 givenname: Takashi surname: Murayama fullname: Murayama, Takashi organization: Department of Cellular and Molecular Pharmacology, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan – sequence: 3 givenname: Naoyuki surname: Tetsuo fullname: Tetsuo, Naoyuki organization: Department of Cellular and Molecular Pharmacology, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan – sequence: 4 givenname: Minako surname: Hoshiai fullname: Hoshiai, Minako organization: Pediatric Heart Center, Department of Pediatrics, Yamanashi Prefectural Central Hospital, Kofu, Japan – sequence: 5 givenname: Hiroaki surname: Kise fullname: Kise, Hiroaki organization: Pediatric Heart Disease and Adult Congenital Heart Disease Center, Showa University Hospital, Tokyo, Japan – sequence: 6 givenname: Masao surname: Yoshinaga fullname: Yoshinaga, Masao organization: Department of Pediatrics, National Hospital Organization Kagoshima Medical Center, Kagoshima, Japan – sequence: 7 givenname: Hisaaki surname: Aoki fullname: Aoki, Hisaaki organization: Department of Pediatric Cardiology, Osaka Women’s and Children’s Hospital, Osaka, Japan – sequence: 8 givenname: Megumi surname: Fukuyama fullname: Fukuyama, Megumi organization: Department of Cardiovascular Medicine, Shiga University of Medical Science, Otsu, Japan – sequence: 9 givenname: Yimin surname: Wuriyanghai fullname: Wuriyanghai, Yimin organization: Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan – sequence: 10 givenname: Yuko orcidid: 0000-0001-8533-8040 surname: Wada fullname: Wada, Yuko organization: Department of Cardiovascular Medicine, Shiga University of Medical Science, Otsu, Japan – sequence: 11 givenname: Koichi orcidid: 0000-0002-6125-0789 surname: Kato fullname: Kato, Koichi organization: Department of Cardiovascular Medicine, Shiga University of Medical Science, Otsu, Japan – sequence: 12 givenname: Takeru surname: Makiyama fullname: Makiyama, Takeru organization: Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan – sequence: 13 givenname: Takeshi surname: Kimura fullname: Kimura, Takeshi organization: Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan – sequence: 14 givenname: Takashi surname: Sakurai fullname: Sakurai, Takashi organization: Department of Cellular and Molecular Pharmacology, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan – sequence: 15 givenname: Minoru orcidid: 0000-0002-9029-2339 surname: Horie fullname: Horie, Minoru organization: Department of Cardiovascular Medicine, Shiga University of Medical Science, Otsu, Japan – sequence: 16 givenname: Nagomi surname: Kurebayashi fullname: Kurebayashi, Nagomi email: nagomik@juntendo.ac.jp organization: Department of Cellular and Molecular Pharmacology, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan – sequence: 17 givenname: Seiko orcidid: 0000-0003-1209-8896 surname: Ohno fullname: Ohno, Seiko email: sohno@ncvc.go.jp organization: Department of Bioscience and Genetics, National Cerebral and Cardiovascular Center, 6-1 Kishibe-Shinmachi, Suita, Osaka 564-8565, Japan |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34661651$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkEtr3DAUhUVJyavZd1W0LBQ3sl62liWkTWCgFGZvrqXrjostuZJV8Ka_PRpm0m0RSGfxnYP4bsiFDx4JeV-zzzUz4h5zDAtYLAF6rtgbcl0rwSvODL8omRlTqZqbK3KT0i_GWMONuiRXQmpda1Vfk7-7kFIVhmrI3q5j8HTOKxxDoqOnFqIbwdK4gQ9u9EgjWlzWEKk9gPc4FSQnpH8gjiEnum4LJhoGCjEetvUwj3AcslMu7Z90CuX6sadp8y6GGd-RtwNMCe_O7y3Zf33cPzxVu-_fnh--7CorpVorB32LvHZ80FhOq4RD0SrVgmvQSS2t5K0eDBip2qbvlRbGKI0tNthIELfk42l2ieF3xrR285gsThN4LL_uuGqFYFoqVVB2Qm0sZiIO3RLHGeLW1aw7Su9epXdn6aXy4bye-xndv8Kr5QJ8OgEhL_-fewGlNpSy |
CitedBy_id | crossref_primary_10_1016_j_coph_2022_102327 crossref_primary_10_1536_ihj_23_652 crossref_primary_10_3390_biom12081030 crossref_primary_10_1155_2022_6491084 crossref_primary_10_3389_fcvm_2022_891399 crossref_primary_10_1085_jgp_202112869 crossref_primary_10_1093_europace_euad210 crossref_primary_10_1016_j_ccep_2023_05_003 crossref_primary_10_1093_europace_euab283 crossref_primary_10_1093_europace_euad156 crossref_primary_10_1093_europace_euad220 crossref_primary_10_1371_journal_pone_0277242 crossref_primary_10_1161_CIRCEP_122_011387 crossref_primary_10_1038_s41467_022_30429_x crossref_primary_10_1124_molpharm_123_000720 crossref_primary_10_1016_j_bcp_2022_115059 crossref_primary_10_1111_1440_1681_13722 crossref_primary_10_1007_s12181_023_00622_3 crossref_primary_10_1155_2024_5759229 crossref_primary_10_3390_biomedicines10010106 crossref_primary_10_1085_jgp_202213089 |
Cites_doi | 10.1073/pnas.1419795112 10.1146/annurev.physiol.70.113006.100455 10.1161/CIRCEP.114.002217 10.1016/j.bpj.2013.08.024 10.1038/ncomms5153 10.1253/circj.CJ-19-0720 10.1016/j.joa.2015.09.008 10.1007/s00431-015-2689-z 10.1161/01.CIR.103.2.196 10.1371/journal.pone.0130606 10.1016/j.hrthm.2016.10.015 10.1085/jgp.201611624 10.1007/s00380-016-0869-z 10.1073/pnas.0706573104 10.1161/01.RES.0000192146.85173.4b 10.1371/journal.pone.0130329 10.1161/01.RES.0000235869.50747.e1 10.1073/pnas.95.6.2979 10.1161/CIRCRESAHA.120.316819 10.1016/j.jelectrocard.2016.09.006 10.1016/j.hrthm.2007.02.026 |
ContentType | Journal Article |
Copyright | Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2021. For permissions, please email: journals.permissions@oup.com. 2021 Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2021. For permissions, please email: journals.permissions@oup.com. |
Copyright_xml | – notice: Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2021. For permissions, please email: journals.permissions@oup.com. 2021 – notice: Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2021. For permissions, please email: journals.permissions@oup.com. |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
DOI | 10.1093/europace/euab250 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | CrossRef MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1532-2092 |
EndPage | 510 |
ExternalDocumentID | 10_1093_europace_euab250 34661651 10.1093/europace/euab250 |
Genre | Journal Article |
GroupedDBID | --- --K .2P .I3 .XZ .ZR 0R~ 1B1 1TH 29G 2WC 4.4 48X 53G 5GY 5VS 5WA 6PF 70D AABZA AACZT AAJKP AAJQQ AAMVS AAOGV AAPNW AAPQZ AAPXW AASNB AAUAY AAUQX AAVAP AAWTL ABEUO ABIXL ABJNI ABKDP ABNHQ ABNKS ABPTD ABQLI ABQTQ ABWST ABXVV ABZBJ ACGFS ACPRK ACUFI ACUTO ADBBV ADEYI ADEZT ADGZP ADHKW ADHZD ADJQC ADOCK ADRIX ADRTK ADVEK ADYVW ADZXQ AEGPL AEJOX AEKSI AEMDU AENEX AENZO AEPUE AETBJ AEWNT AFFZL AFIYH AFOFC AFXAL AFXEN AGINJ AGKEF AGQXC AGSYK AGUTN AHMBA AHXPO AIJHB AJEEA ALMA_UNASSIGNED_HOLDINGS ALUQC APIBT APWMN ATGXG AXUDD BAWUL BAYMD BCRHZ BEYMZ BHONS BTRTY BVRKM C1A CAG CDBKE COF CS3 CZ4 DAKXR DIK DILTD DU5 D~K E3Z EBD EBS EE~ EJD EMOBN ENERS F5P F9B FECEO FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 H5~ HAR HW0 HZ~ IHE IOX J21 KBUDW KOP KQ8 KSI KSN M-Z M41 M49 MHKGH N9A NGC NOMLY NOYVH NQ- NTWIH NU- O0~ O9- OAUYM OAWHX ODMLO OJQWA OJZSN OK1 OPAEJ OVD P2P PAFKI PEELM PQQKQ Q1. Q5Y RD5 RHF RIG ROL ROX RPM RPZ RUSNO RW1 RXO SEL SV3 TCURE TEORI TJX TOX TR2 UHS VVN W8F WOQ X7H YAYTL YKOAZ YXANX ZKX ~91 CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
ID | FETCH-LOGICAL-c445t-dab8e21d2f6e6e6853de38558ad7ed464c4286f9a94587bb5639956e8e7e74a3 |
IEDL.DBID | TOX |
ISSN | 1099-5129 |
IngestDate | Fri Oct 25 21:24:33 EDT 2024 Fri Aug 23 01:57:48 EDT 2024 Wed Oct 16 00:41:34 EDT 2024 Wed Aug 28 03:16:20 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Keywords | Loss of function QT prolongation Mutation Arrhythmias Ryanodine receptor Ventricular fibrillation RyR2 |
Language | English |
License | This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model) Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2021. For permissions, please email: journals.permissions@oup.com. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c445t-dab8e21d2f6e6e6853de38558ad7ed464c4286f9a94587bb5639956e8e7e74a3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0002-9029-2339 0000-0002-6125-0789 0000-0001-8533-8040 0000-0003-1209-8896 |
PMID | 34661651 |
PQID | 2583306455 |
PQPubID | 23479 |
PageCount | 14 |
ParticipantIDs | proquest_miscellaneous_2583306455 crossref_primary_10_1093_europace_euab250 pubmed_primary_34661651 oup_primary_10_1093_europace_euab250 |
PublicationCentury | 2000 |
PublicationDate | 2022-03-02 |
PublicationDateYYYYMMDD | 2022-03-02 |
PublicationDate_xml | – month: 03 year: 2022 text: 2022-03-02 day: 02 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | Europace (London, England) |
PublicationTitleAlternate | Europace |
PublicationYear | 2022 |
Publisher | Oxford University Press |
Publisher_xml | – name: Oxford University Press |
References | 34850886 - Europace. 2022 Mar 2;24(3):494-496 Roston (2022030308001107200_euab250-B9) 2017; 50 Suzuki (2022030308001107200_euab250-B16) 2014; 5 Claycomb (2022030308001107200_euab250-B17) 1998; 95 Taniguchi (2022030308001107200_euab250-B13) 2017; 32 Kryshtal (2022030308001107200_euab250-B20) 2021; 128 Yaniv (2022030308001107200_euab250-B21) 2013; 105 Fujii (2022030308001107200_euab250-B11) 2017; 14 Shigemizu (2022030308001107200_euab250-B18) 2015; 10 Sumitomo (2022030308001107200_euab250-B7) 2016; 32 Priori (2022030308001107200_euab250-B5) 2001; 103 Nozaki (2022030308001107200_euab250-B14) 2020; 84 Jiang (2022030308001107200_euab250-B8) 2007; 104 Zhao (2022030308001107200_euab250-B10) 2015; 112 Murayama (2022030308001107200_euab250-B15) 2015; 10 Jiang (2022030308001107200_euab250-B3) 2005; 97 Bers (2022030308001107200_euab250-B1) 2008; 70 Baruteau (2022030308001107200_euab250-B19) 2016; 175 Roston (2022030308001107200_euab250-B2) 2015; 8 Liu (2022030308001107200_euab250-B4) 2006; 99 Uehara (2022030308001107200_euab250-B6) 2017; 149 Tester (2022030308001107200_euab250-B12) 2007; 4 |
References_xml | – volume: 112 start-page: E1669 year: 2015 ident: 2022030308001107200_euab250-B10 article-title: Arrhythmogenesis in a catecholaminergic polymorphic ventricular tachycardia mutation that depresses ryanodine receptor function publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.1419795112 contributor: fullname: Zhao – volume: 70 start-page: 23 year: 2008 ident: 2022030308001107200_euab250-B1 article-title: Calcium cycling and signaling in cardiac myocytes publication-title: Annu Rev Physiol doi: 10.1146/annurev.physiol.70.113006.100455 contributor: fullname: Bers – volume: 8 start-page: 633 year: 2015 ident: 2022030308001107200_euab250-B2 article-title: Catecholaminergic polymorphic ventricular tachycardia in children: analysis of therapeutic strategies and outcomes from an international multicenter registry publication-title: Circ Arrhythm Electrophysiol doi: 10.1161/CIRCEP.114.002217 contributor: fullname: Roston – volume: 105 start-page: 1551 year: 2013 ident: 2022030308001107200_euab250-B21 article-title: Mechanisms of beat-to-beat regulation of cardiac pacemaker cell function by Ca(2)(+) cycling dynamics publication-title: Biophys J doi: 10.1016/j.bpj.2013.08.024 contributor: fullname: Yaniv – volume: 5 start-page: 4153 year: 2014 ident: 2022030308001107200_euab250-B16 article-title: Imaging intraorganellar Ca2+ at subcellular resolution using CEPIA publication-title: Nat Commun doi: 10.1038/ncomms5153 contributor: fullname: Suzuki – volume: 84 start-page: 226 year: 2020 ident: 2022030308001107200_euab250-B14 article-title: Co-phenotype of left ventricular non-compaction cardiomyopathy and atypical catecholaminergic polymorphic ventricular tachycardia in association with R169Q, a ryanodine receptor type 2 missense mutation publication-title: Circ J doi: 10.1253/circj.CJ-19-0720 contributor: fullname: Nozaki – volume: 32 start-page: 344 year: 2016 ident: 2022030308001107200_euab250-B7 article-title: Current topics in catecholaminergic polymorphic ventricular tachycardia publication-title: J Arrhythm doi: 10.1016/j.joa.2015.09.008 contributor: fullname: Sumitomo – volume: 175 start-page: 151 year: 2016 ident: 2022030308001107200_euab250-B19 article-title: Evaluation and management of bradycardia in neonates and children publication-title: Eur J Pediatr doi: 10.1007/s00431-015-2689-z contributor: fullname: Baruteau – volume: 103 start-page: 196 year: 2001 ident: 2022030308001107200_euab250-B5 article-title: Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia publication-title: Circulation doi: 10.1161/01.CIR.103.2.196 contributor: fullname: Priori – volume: 10 start-page: e0130606 year: 2015 ident: 2022030308001107200_euab250-B15 article-title: Divergent activity profiles of type 1 ryanodine receptor channels carrying malignant hyperthermia and central core disease mutations in the amino-terminal region publication-title: PLoS One doi: 10.1371/journal.pone.0130606 contributor: fullname: Murayama – volume: 14 start-page: 98 year: 2017 ident: 2022030308001107200_euab250-B11 article-title: A type 2 ryanodine receptor variant associated with reduced Ca(2+) release and short-coupled torsades de pointes ventricular arrhythmia publication-title: Heart Rhythm doi: 10.1016/j.hrthm.2016.10.015 contributor: fullname: Fujii – volume: 149 start-page: 199 year: 2017 ident: 2022030308001107200_euab250-B6 article-title: Extensive Ca2+ leak through K4750Q cardiac ryanodine receptors caused by cytosolic and luminal Ca2+ hypersensitivity publication-title: J Gen Physiol doi: 10.1085/jgp.201611624 contributor: fullname: Uehara – volume: 32 start-page: 229 year: 2017 ident: 2022030308001107200_euab250-B13 article-title: Prominent QTc prolongation in a patient with a rare variant in the cardiac ryanodine receptor gene publication-title: Heart Vessels doi: 10.1007/s00380-016-0869-z contributor: fullname: Taniguchi – volume: 104 start-page: 18309 year: 2007 ident: 2022030308001107200_euab250-B8 article-title: Loss of luminal Ca2+ activation in the cardiac ryanodine receptor is associated with ventricular fibrillation and sudden death publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.0706573104 contributor: fullname: Jiang – volume: 97 start-page: 1173 year: 2005 ident: 2022030308001107200_euab250-B3 article-title: Enhanced store overload-induced Ca2+ release and channel sensitivity to luminal Ca2+ activation are common defects of RyR2 mutations linked to ventricular tachycardia and sudden death publication-title: Circ Res doi: 10.1161/01.RES.0000192146.85173.4b contributor: fullname: Jiang – volume: 10 start-page: e0130329 year: 2015 ident: 2022030308001107200_euab250-B18 article-title: Exome analyses of long QT syndrome reveal candidate pathogenic mutations in calmodulin-interacting genes publication-title: PLoS One doi: 10.1371/journal.pone.0130329 contributor: fullname: Shigemizu – volume: 99 start-page: 292 year: 2006 ident: 2022030308001107200_euab250-B4 article-title: Arrhythmogenesis in catecholaminergic polymorphic ventricular tachycardia: insights from a RyR2 R4496C knock-in mouse model publication-title: Circ Res doi: 10.1161/01.RES.0000235869.50747.e1 contributor: fullname: Liu – volume: 95 start-page: 2979 year: 1998 ident: 2022030308001107200_euab250-B17 article-title: HL-1 cells: a cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.95.6.2979 contributor: fullname: Claycomb – volume: 128 start-page: 321 year: 2021 ident: 2022030308001107200_euab250-B20 article-title: RYR2 channel inhibition is the principal mechanism of flecainide action in CPVT publication-title: Circ Res doi: 10.1161/CIRCRESAHA.120.316819 contributor: fullname: Kryshtal – volume: 50 start-page: 227 year: 2017 ident: 2022030308001107200_euab250-B9 article-title: A novel RYR2 loss-of-function mutation (I4855M) is associated with left ventricular non-compaction and atypical catecholaminergic polymorphic ventricular tachycardia publication-title: J Electrocardiol doi: 10.1016/j.jelectrocard.2016.09.006 contributor: fullname: Roston – volume: 4 start-page: 733 year: 2007 ident: 2022030308001107200_euab250-B12 article-title: A mechanism for sudden infant death syndrome (SIDS): stress-induced leak via ryanodine receptors publication-title: Heart Rhythm doi: 10.1016/j.hrthm.2007.02.026 contributor: fullname: Tester |
SSID | ssj0007295 |
Score | 2.4817536 |
Snippet | Abstract
Aims
Gain-of-function mutations in RYR2, encoding the cardiac ryanodine receptor channel (RyR2), cause catecholaminergic polymorphic ventricular... Gain-of-function mutations in RYR2, encoding the cardiac ryanodine receptor channel (RyR2), cause catecholaminergic polymorphic ventricular tachycardia (CPVT).... AIMSGain-of-function mutations in RYR2, encoding the cardiac ryanodine receptor channel (RyR2), cause catecholaminergic polymorphic ventricular tachycardia... |
SourceID | proquest crossref pubmed oup |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 497 |
SubjectTerms | Arrhythmias, Cardiac - diagnosis Arrhythmias, Cardiac - genetics Calcium - metabolism HEK293 Cells Humans Long QT Syndrome - diagnosis Long QT Syndrome - genetics Mutation Ryanodine Receptor Calcium Release Channel - genetics Ryanodine Receptor Calcium Release Channel - metabolism Tachycardia, Ventricular - diagnosis Tachycardia, Ventricular - genetics |
Title | Loss-of-function mutations in cardiac ryanodine receptor channel cause various types of arrhythmias including long QT syndrome |
URI | https://www.ncbi.nlm.nih.gov/pubmed/34661651 https://search.proquest.com/docview/2583306455 |
Volume | 24 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1LS8NAEF6kB_Eivq0vVujFw2KzjzyOIpYiVhEi9BY2uxNaaJPStEIv_nZnk7Qg9lACIYdlAvMt-ebLl5kQ0lFS-5lnQ5aGIFGgSMs0gGDWkyoyWWR41bc2ePf7X_J1qIbNnO1yi4UfiUc3pAL1I-CFTnmlz91UNNy78cdw89TFIlFVzmYUMUdijSW5LcAfCvrT1vavuqxYpndEDpvykD7VeB6TPchPyP6gMcBPyc8bRmRFxhwfuZzS6bI200s6zqmp8DZ0vtJ5gawEFB9oMENdTV2Hbw4TXLIsgX6jREbNT90b2JIWGdXz-Wi1GE3H2gUyk6XjNDop8PQZ0_VcgzMS917i5z5rfqHAjJRqwaxGDLhneeYDHsjNFkSoVKhtAFb60qD88LNIR1KFQZoqv2p1hRACCKQW56SVFzlcEiqML7rcBLabedKGXawbuTbCRpnFqsmYNnlYJzWZ1YMyktrgFskagKQBoE06mPUdlt2vYUlw0zsnQ-eAyUm46xVzk_ZUm1zUeG2iCYklh6-8q91uck0OuOtocJ-V8RvSWsyXcIt1xiK9qzbYLxOr1Rc |
link.rule.ids | 315,783,787,1607,27936,27937 |
linkProvider | Oxford University Press |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Loss-of-function+mutations+in+cardiac+ryanodine+receptor+channel+cause+various+types+of+arrhythmias+including+long+QT+syndrome&rft.jtitle=Europace+%28London%2C+England%29&rft.au=Hirose%2C+Sayako&rft.au=Murayama%2C+Takashi&rft.au=Tetsuo%2C+Naoyuki&rft.au=Hoshiai%2C+Minako&rft.date=2022-03-02&rft.pub=Oxford+University+Press&rft.issn=1099-5129&rft.eissn=1532-2092&rft.volume=24&rft.issue=3&rft.spage=497&rft.epage=510&rft_id=info:doi/10.1093%2Feuropace%2Feuab250&rft.externalDocID=10.1093%2Feuropace%2Feuab250 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1099-5129&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1099-5129&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1099-5129&client=summon |